Facet browsing currently unavailable
Page 1 of 1 results
Sort by: relevance publication year
Showing DOI matching
10.1016/j.resmer.2020.100795
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study JOURNAL ARTICLE published November 2021 in Respiratory Medicine and Research |